Burosumab - new potent treatment for X-linked hypophosphatemia and tumor-induced osteomalacia

Burosumab - new potent treatment for X-linked hypophosphatemia and tumor-induced osteomalacia

Introduction and purpose: Elevated FGF23 in X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO) leads to systemic hypophosphatemia, several musculoskeletal manifestations and rickets in children. In this review we describe advances in the management of XLH and TIO using burosumab...

Full description

Bibliographic Details
Main Authors: Magda Wojtuś, Sebastian Tomaszuk, Karolina Wąsik
Format: Article
Language:English
Published: Kazimierz Wielki University 2023-07-01
Series:Journal of Education, Health and Sport
Subjects:
burosumab
health
XLH
TIO
Online Access:https://apcz.umk.pl/JEHS/article/view/44798

Similar Items

Similar Items